Nanobiotix (France) a preclinical-stage company developing a targeted radiotherapy platform for the treatment of gliblastoma multiform, head and neck and lung cancer, closed an $11M Series C financing. Participants include CIC Vizille Capital, Masseran Gestion, Matignon Technologies, OTC Asset Management, Cap Decisif and Amorçage Rhône-Alpes.